Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
Status:
Completed
Trial end date:
2017-06-22
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label trial to assess the long-term safety and efficacy of
Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with
treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet
syndrome (DS). All participants have rolled over from previous trials: INS011-14-029
(NCT02324673) and INS011-15-054 (NCT02551731).